Compass Therapeutics sees cash runway into 1Q27

As of September 30, 2024, cash and marketable securities were $135 million as compared to $152 million as of December 31, 2023, which gives a cash runway into the first quarter of 2027. During the first nine months of 2024, Compass decreased its cash position by $17 million, primarily by cash used in operating activities partially offset by $18 million cash received from issuance of stock through its at-the-market offering program.